Herpes zoster is a common condition, and involvement of the trigeminal nerve results in herpes zoster ophthalmicus (HZO). Acute keratitis is one of the most common of these ocular complications associated with HZO. The findings associated with and the management of acute zoster keratitis will be reviewed.
INTRODUCTION
The varicella-zoster virus (VZV) is found worldwide and causes two distinct disease entities. The first is a primary infection varicella, more commonly known as chickenpox. Spread via respiratory droplets, the virus is easily contracted by susceptible individuals [1, 2] . Prior to introduction of the varicella vaccination in the United States in 1995, almost all children developed chickenpox with more than 95% of the population in the United States having positive VZV serologies [3] .
After primary infection of VZV either through chickenpox or varicella vaccination, the virus then migrates and remains dormant within the sensory spinal or cerebral ganglia. Reactivation of this latent virus results in the second clinical manifestation of VZV known as herpes zoster, or shingles. Herpes zoster presents acutely with pain and vesicular lesions of the skin in a single dermatomal distribution. It may be preceded by fever, malaise, and headaches. Lesions may continue to develop over the course of a week, but may then take several weeks to resolve entirely.
EPIDEMIOLOGY OF HERPES ZOSTER
With a near ubiquitous seropositivity for VZV in adults in the United States [3] , the lifetime risk for an individual to develop herpes zoster is approximately 30% [4] . It is estimated that there are approximately one million new cases of herpes zoster diagnosed annually in the United States [2,5 & ,6] , and an incidence rate of approximately 4.6 cases per 1000 person-years [6] . This incidence rate increases substantially with age [6, 7] .
Interestingly, the incidence rate of herpes zoster is known to be increasing [7,8 && ] . In one populationbased cohort study done in the Minnesota comparing patient data from 1945 to 1960 and 1980 to 2007, the incidence of herpes zoster significantly increased in all age groups and genders [8 && ]. A second study reviewing Medicare data between 1992 and 2010 also demonstrated a 39% increase in the annual incidence of herpes zoster during that time period [7] . It is not known what is driving this increase in herpes zoster although there are several hypotheses. One of the most commonly iterated hypothesis is that the introduction of the varicella vaccination in childhood has consequently decreased the natural boosting of our immunity from exposure to wild-type VZV leaving us more susceptible to developing herpes zoster. However, both the previously referenced studies above found that the incidence of herpes zoster was on the rise even prior to the development of the childhood vaccination program in 1996, and that the rate of increase has not changed [7,8 && ] . This suggests that other yet-unknown factors are driving this increase rather than the introduction of widespread vaccination for varicella.
Although the root cause for the increase in herpes zoster remains unclear, what is clear is that with the increase in cases of herpes zoster also comes an increase in associated complications including herpes zoster ophthalmicus (HZO) [9 && ]. Moreover, it appears that not only is the rate of herpes zoster increasing, but the frequency of eye involvement in HZO cases is also increasing [10] . In the Minnesota cohort of patients, they found a 23% overall increase in herpes zoster eye complications between 1980 and 2007 [10] .
HERPES ZOSTER OPHTHALMICUS
HZO occurs when there is reactivation of VZV involving the ophthalmic branch of the trigeminal nerve (V1). It is estimated that 10-20% of cases of herpes zoster present as HZO [2, 11] . It is important to remember that HZO may occur with or without ocular involvement. The frontal branch which innervates the skin of the forehead and the upper eyelid is most frequently involved in HZO, but it is involvement of both branches of the nasociliary nerve that is the strongest predictor of ocular inflammation and corneal anesthesia [12, 13] . Involvement of the nasociliary nerve results in lesions involving the skin of the upper and lower eyelids and the tip of the nose. This skin involvement of the tip of the nose from VZV is commonly referred to as Hutchinson sign [12] . In addition to this distribution of periocular and nasal skin innervation, the nasocialiary nerve also innervates the cornea, conjunctiva, sclera, and uvea, which results in the ocular findings associated with HZO. Hutchinson sign is classically associated with ocular involvement, although it is present in less than a quarter of patients with HZO [14 && ]. As with other dermatomal involvement, patients with HZO may experience prodromal symptoms of fever, malaise, headaches, and pain around the eye. Ocular complications can include conjunctivitis, keratitis, iritis/uveitis, episcleritis/scleritits, extraocular motor nerve palsies, retinal perivasculitis and necrosis, and optic neuritis [ 
ACUTE KERATITIS ASSOCIATED WITH HERPES ZOSTER OPHTHALMICUS
Acute keratitis associated with HZO may present in several different ways and typically occurs within 1 month of onset of dermatitis. VZV may affect the epithelial, stromal, or endothelial layers of the cornea.
One of the early findings of HZO with ocular involvement are punctate epithelial keratitis and pseudodendrites. These types of epithelial keratitis are observed in 5-51% of patients with ocular involvement in HZO [10,14 && ,15-17] . Punctate epithelial keratitis typically appears 2 days after the vesicular skin eruption and may either be transient or coalesce into pseudodendrites around day 4 to 6 in acute HZO [17] . These small, fine pseudodendrites have a similar branching pattern to dendrites seen in herpes simplex virus (HSV) keratitis, however, they are not true epithelial defects and lack the central ulceration of HSV dendrites. The pseudodendrites are composed of swollen, heaped up epithelial
KEY POINTS
The incidence rate of herpes zoster is increasing whereas the age of presentation is declining. Ocular complications related to HZO have also been increasing in number.
Acute keratitis is a frequent finding in patients who develop HZO with ocular manifestations. The disease may affect any layer of the cornea, but patients who have epithelial or stromal keratitis are most at risk of vision loss.
There is no standardized treatment recommendation for acute keratitis in HZO. Topical antivirals have been used successfully to manage recalcitrant epithelial keratitis. Topical corticosteroids may also be necessary to manage the inflammation associated with HZO, but should be used with caution as it can be difficult to taper off without rebound inflammation occurring.
Zoster vaccinations are effective at decreasing the risk of developing herpes zoster although the effect may wane with time. The vaccination may also decrease the duration and severity of herpes zoster in patients who have been previously vaccinated.
cells which may appear 'stuck on'. Usually located in the peripheral cornea, these pseudodendrites lack the terminal bulb appearance of dendrites associated with HSV ( Fig. 1) . VZV has been cultured from scraping of the abnormal epithelial cells, suggesting that these findings are related to active viral infection [17] , and VZV DNA may persist on the corneal surface of the eye for as long as 1 month after an acute HZO episode [18] . Epithelial keratitis may resolve spontaneously or may progress on to anterior stromal infiltrates in approximately half of these patients [17] .
Anterior stromal infiltrates typically develop around day 10 of an acute HZO episode [17] . These lesions almost always appear after the epithelial disease findings and often develop under the areas of prior epithelial keratitis. Stromal keratitis has been observed in 6-16% of patients with ocular manifestations [14 && ,15,16] . In addition to leaving behind long-term nummular corneal scarring (Fig. 2) , anterior stromal keratitis may also result in areas of lipid keratopathy (Fig. 3) and dellen [17] . Stromal keratitis is traditionally thought to be an immune-mediated response to viral antigens. However, in a recent case report of recurrent herpes zoster keratitis after zoster vaccination may suggest a different pathophysiology for zoster stromal keratitis [19 && ]. In this case, the cornea ultimately perforated and a penetrating keratoplasty was performed which allowed the authors to obtain electron microscopy of the excised cornea [19 && ]. Electron microscopy demonstrated herpetic virus capsids within approximately half of the degenerativeappearing keratocytes [19 && ]. This finding may suggest that stromal keratitis is not simply an immunemediated response to viral antigens, but the result of active infection of the keratocytes [20] .
Keratouveitis and endotheliitis is another manifestation of acute HZO. A less common manifestation than epithelial keratitis or anterior stromal keratitis, keratouveitis/endotheliitis occurs in approximately 1-7% of patients [14 && ,15] . These patients often present between day 4 and day 7 of the acute disease with sudden onset corneal edema and keratic precipitates [17] . The corneal edema may present in a disciform appearance, and a complement-mediated immune Wessely ring may also be seen in some cases. The degree of anterior chamber reaction is variable, but may be severe with associated hypopyon or hyphema from an associated vasculitis. Patients with keratouveitis may also have concomitant elevated intraocular pressures. This type of keratouveitis and endotheliitis can lead to long-term endothelial cell loss and corneal decompensation. The exact mechanism of disease development is not known, but VZV particles have been detected both at the level of the endothelium and in the aqueous humor [21, 22] . Finally, sclerokeratitis is a less common finding and develops later in the acute phase of the disease. A crescent-shaped area of peripheral corneal infiltrates develops adjacent to an area of scleritis. These lesions can cause significant neovascularization, corneal thinning, scarring, and lipid deposition (Fig. 4) .
In patients with HZO, epithelial keratitis and stromal keratitis have been found to be risks factors for vision loss after resolution of the acute disease because of the development of long-term corneal scarring or haze [14 && ]. In the Minnesota cohort of patients, 6% of patients were found to develop longterm vision loss [10] . Thus, it is important to correctly diagnose and manage HZO to minimize the long-term complications.
Although the diagnosis of HZO may appear straight forward in the context of an elderly or immunocompromised patient who presents with an obvious dermatomal rash in the trigeminal distribution, it is important to remember that younger, healthy patients are becoming increasingly afflicted with this disease. In a study of patients with HZO in Hong Kong, 42.5% of patients with ocular involvement were less than 60 years old [14 && ]. Other studies have demonstrated a similar downward trend in the age of onset of HZO over the past two decades particularly in patients over the age of 40 with the peak incidence occurring between the ages of 50 and 59 [9 && ,23,24] . Another entity which can confound early diagnosis and management of the disease is herpes zoster sine herpetica. In these patients, a vesicular skin rash does not occur but the secondary effects such as keratitis and keratouveitis are present [25] .
TREATMENT OF ACUTE HERPES ZOSTER KERATITIS
The current recommendation for the management of acute HZO is to initiate oral antiviral medications within 72 h of onset of vesicular lesions. The recommended adult dosages for oral antivirals are as follows: valacyclovir 1,000 mg 3Â/day, famciclovir 500 mg 3Â/day, or acyclovir 800 mg 5Â/day. Valacyclovir, acyclovir, and famciclovir have been shown to be comparable in terms of rate of resolution of cutaneous lesions [26, 27] . Valacyclovir and acyclovir also appear to have a similar effect in prevention of ocular complications in HZO [16] .
As for reducing pain associated with herpes zoster and postherpetic neuralgia, no significant difference was found between valacyclovir and famciclovir [27] . However, whether acyclovir is as effective as valacyclovir in managing herpes zoster pain is debatable. In one early study, valacyclovir appeared to significantly decrease the time to resolution of herpes zoster associated pain and the duration of postherpetic neuralgia and chronic pain when compared to acyclovir [26] . However, a later study was unable to support those same findings and found that the duration of pain and the percentage of patients with postherpetic neuralgia were similar between patients treated with valacyclovir and those treated with acyclovir [16] .
Unlike the management of skin lesions, there is less consensus for how to treat acute ophthalmic complications such as keratitis. Topical ganciclovir 0.15% gel has been shown to be helpful in the management of pseudodendrites even after prior poor response to oral antivirals [28] . The use of topical corticosteroids to help control inflammation associated with ocular involvement of HZO is even more controversial. While the management of stromal keratitis and keratouveitis/iritis may require initiation of topical corticosteroids, once started, it may be difficult to taper patients off the drops. Drops should be tapered to the lowest amount required to control the ocular findings while preventing rebound inflammation. Patients may ultimately require low doses of topical corticosteroids chronically and should be warned of potential sideeffects such as development of cataracts and steroidinduced glaucoma.
Finally, secondary complications from ocular involvement of HZO must be addressed. Most notably is the management of ocular surface complications from neurotrophic keratopathy. It can be difficult to discern when acute epithelial keratitis transitions into neurotrophic keratitis where patients may have nonhealing epithelial defects from the underlying neurotrophic disease and epithelial toxicity from topical antivirals. Aggressive ocular surface lubrication, punctal occlusion, bandage contact lenses, and lateral tarsorrhaphies may be necessary in these situations to help with reepithelialization and stabilization of the ocular surface, and topical antibiotics should be initiated to decrease the risk of a microbial superinfection. Unfortunately, these more challenging patients will more often than not have permanent vision loss from these ocular complications of HZO.
THE IMPACT HERPES ZOSTER VACCINATION
Ultimately, prevention of herpes zoster is key to eliminating the many long-term debilitating complications of this disease.
Since 2006, a live attenuated single-dose vaccine (Zostavax, Merck and Co., Inc., Whitehouse Station, NJ, USA) for the prevention of herpes zoster has been available in the United States. The strain of VZV used in the zoster vaccine is the same as that used in the varicella vaccine but with a minimum potency that is at least 14 times that of the varicella vaccine [29] . In the phase III vaccine trial, the vaccine reduced the risk of developing zoster by 51.3% and demonstrated a 66.5% efficacy for preventing postherpetic neuralgia [30] . Additionally, the vaccine shortened the duration and decreased the severity of disease in patients who developed herpes zoster despite the vaccine [30] . The live attenuated vaccine is recommended for all patients at least 60 years of age except patients with primary and acquired immunodeficiency, pregnant women, and those with a history of anaphylaxis to components of the vaccine [29] . ]. Longer-term experience with this new recombinant vaccine will help us to understand better the benefits and potential side effects of this vaccine.
CONCLUSION
Herpes zoster is a growing health concern. Traditionally thought of as a disease of the elderly, not only is the incidence of herpes zoster on the rise, the average age at presentation is declining. The reasons for these trends are unclear, but as clinicians, being aware of these changes can help with earlier diagnosis and timely management to prevent complications associated with herpes zoster.
The complications of herpes zoster can significantly affect the quality of life for patients. In the context of HZO, ocular complications such as keratitis can lead to a loss of best vision. At this time, there are no standard treatment recommendations for the management of herpes zoster keratitis. Further research is needed to establish the optimal treatment for herpes zoster related eye complications. Currently, the Zoster Eye Disease Study is underway which seeks to determine whether or not a 12-month course of oral valacyclovir will reduce the rate of anterior segment disease in patients with HZO [33 & ]. Finally, the long-term effects of the new recombinant zoster vaccination on herpes zoster is yet to be determined. Nevertheless, healthcare providers should continue to educate their patients on the availability of the zoster vaccines and on the benefits they provide to decreasing the risk of developing herpes zoster and its associated complications.
